NCT04566978

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

Completed EARLY_PHASE1 Last updated 23 April 2025

What this trial tests

EARLY_PHASE1 trial testing 89Zr-DFO-REGN3767 in Large B-cell Lymphoma in 7 participants. Completed in 21 March 2025.

Timeline

11 September 2020

Primary endpoint
21 March 2025

21 March 2025

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	diagnostic
Enrollment	7
Start date	11 September 2020
Primary completion	21 March 2025
Estimated completion	21 March 2025
Sites	1 location across United States

Drugs / interventions tested

• 89Zr-DFO-REGN3767 — full drug profile →
• PET/CT

Conditions studied

• Large B-cell Lymphoma — all drugs for Large B-cell Lymphoma →
• DLBCL — all drugs for DLBCL →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Large B-cell Lymphoma or DLBCL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purposes of this study include:

Looking at the way the body absorbs, distributes, and gets rid of 89Zr-DFO-REGN3767

Finding the best dose amount of 89Zr-DFO-REGN3767

Finding the best time for PET scanning after injection of 89Zr-DFO-REGN3767

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
   Cai L, Li Y, Tan J, Xu L, et al · · 2023 · cited 232× · PMID 37670328 · DOI 10.1186/s13045-023-01499-1
2. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
   Wang Y, Zhang H, Liu C, Wang Z, et al · · 2022 · cited 179× · PMID 35978433 · DOI 10.1186/s13045-022-01325-0
3. Understanding LAG-3 Signaling.
   Chocarro L, Blanco E, Zuazo M, Arasanz H, et al · · 2021 · cited 154× · PMID 34067904 · DOI 10.3390/ijms22105282
4. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
   Pansy K, Uhl B, Krstic J, Szmyra M, et al · · 2021 · cited 87× · PMID 34948104 · DOI 10.3390/ijms222413311
5. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
   Lee JB, Ha SJ, Kim HR. · · 2021 · cited 81× · PMID 34025438 · DOI 10.3389/fphar.2021.681320
6. Clinical landscape of LAG-3-targeted therapy.
   Chocarro L, Blanco E, Arasanz H, Fernández-Rubio L, et al · · 2022 · cited 69× · PMID 35755891 · DOI 10.1016/j.iotech.2022.100079
7. LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors.
   Sauer N, Szlasa W, Jonderko L, Oślizło M, et al · · 2022 · cited 60× · PMID 36077354 · DOI 10.3390/ijms23179958
8. Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor.
   Chocarro L, Bocanegra A, Blanco E, Fernández-Rubio L, et al · · 2022 · cited 57× · PMID 35954196 · DOI 10.3390/cells11152351